Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.49 |
| ▸ | PANK3 | Q9H999 | 8/20 | 0.48 |
| ▸ | SMO | Q99835 | 6/20 | 0.48 |
| ▸ | GPR39 | O43194 | 1/20 | 0.45 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.45 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.45 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29514660 | 0.86 | KDM4E (0.54) | KDM4EALDH1A1L3MBTL1GPR119PANK3 | |
| SCHEMBL3048925 | 0.86 | KDM4E (0.54) | KDM4EALDH1A1L3MBTL1GPR119PANK3 | |
| SCHEMBL14844043 | 0.86 | SMO (0.56) | KDM4EALDH1A1L3MBTL1GPR119PANK3 | |
| SCHEMBL3051541 | 0.84 | CNR2 (0.54) | KDM4EALDH1A1L3MBTL1GPR119PANK3 | |
| SCHEMBL231983 | 0.83 | KDM4E (0.51) | KDM4EALDH1A1L3MBTL1GPR119PANK3 | |
| SCHEMBL30390836 | 0.83 | KDM4E (0.51) | KDM4EALDH1A1L3MBTL1GPR119PANK3 | |
| SCHEMBL14802426 | 0.82 | GPR119 (0.49) | KDM4EALDH1A1L3MBTL1GPR119PANK3 | |
| Hydrochloric Acid SCHEMBL23302464 | 0.81 | KDM4E (0.50) | KDM4EALDH1A1L3MBTL1GPR119PANK3 | |
| Hydrochloric Acid SCHEMBL17455098 | 0.81 | KDM4E (0.50) | KDM4EALDH1A1L3MBTL1GPR119PANK3 | |
| Hydrochloric Acid SCHEMBL21521443 | 0.81 | KDM4E (0.50) | KDM4EALDH1A1L3MBTL1GPR119PANK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103492366-A | Primary amine diazeniumdiolate heterocyclic derivatives | MERCK SHARP & DOHME | 2014-01-01 | — | — | CN | claimed |
| CN-103347385-A | Diazeniumdiolate heterocyclic derivatives | MERCK SHARP & DOHME | 2013-10-09 | — | — | CN | claimed |
| US-20110230467-A1 | 4,6-DIAMINONICOTINAMIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-09-22 | — | — | US | claimed |
| EP-2361902-A1 | 4,6-DIAMINONICOTINAMIDE COMPOUND | Astellas Pharma Inc. (JP) | 2011-08-31 | — | — | EP | claimed |
| CN-114761086-A | Pyridazinones as PARP7 inhibitors | 里邦医疗公司 | 2022-07-15 | — | — | CN | disclosed |
| CN-109776522-B | Substituted heteroaryl compounds, compositions and uses thereof | 广东东阳光药业有限公司 | 2020-12-29 | — | — | CN | disclosed |
| EP-2683687-A1 | PRIMARY AMINE DIAZENIUMDIOLATE HETEROCYCLIC DERIVATIVES | Merck Sharp & Dohme Corp. (US) | 2014-01-15 | — | — | EP | disclosed |
| CN-103492366-A | Primary amine diazeniumdiolate heterocyclic derivatives | MERCK SHARP & DOHME | 2014-01-01 | — | — | CN | disclosed |
| CN-103420981-A | Substituted-pyrrolidinyl-contained thiomorpholine compounds | INST MATERIA MEDICA CAMS | 2013-12-04 | — | — | CN | disclosed |
| CN-103347385-A | Diazeniumdiolate heterocyclic derivatives | MERCK SHARP & DOHME | 2013-10-09 | — | — | CN | disclosed |
| EP-2632255-A1 | DIAZENIUMDIOLATE HETEROCYCLIC DERIVATIVES | Merck Sharp & Dohme Corp. (US) | 2013-09-04 | — | — | EP | disclosed |
| WO-2012122077-A1 | PRIMARY AMINE DIAZENIUMDIOLATE HETEROCYCLIC DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2012-09-13 | — | — | WO | disclosed |
| WO-2012058203-A1 | DIAZENIUMDIOLATE HETEROCYCLIC DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2012-05-03 | — | — | WO | disclosed |
| US-20110230467-A1 | 4,6-DIAMINONICOTINAMIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-09-22 | — | — | US | disclosed |
| EP-2361902-A1 | 4,6-DIAMINONICOTINAMIDE COMPOUND | Astellas Pharma Inc. (JP) | 2011-08-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230467-A1 | 4,6-DIAMINONICOTINAMIDE COMPOUND | JAK3, JAK2, JAK1 | KDM4E 1929/4885ALDH1A1 1378/4885L3MBTL1 2618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.